广藿香醇对人雄激素非依赖性前列腺癌细胞DU145生长的抑制作用及机制

被引:23
作者
蔡剑 [1 ,2 ]
彭成 [1 ]
朱晓燕 [1 ]
张程 [1 ]
万峰 [1 ]
曾文彤 [2 ]
张蜀武 [2 ]
机构
[1] 成都中医药大学
[2] 成都中医药大学附属医院泌尿外科
关键词
广藿香醇; 人前列腺癌细胞DU145; 增殖; 细胞色素C途径; 凋亡;
D O I
暂无
中图分类号
R285.5 [中药实验药理];
学科分类号
100806 [中药药理学];
摘要
目的:观察广藿香醇(pachouli alcohol,PA)对人雄激素非依赖性前列腺癌细胞DU145的凋亡诱导效应及增殖抑制作用,探讨其发生机制。方法:广藿香醇10,20,40,80,160 mg·L-1作用在密度为6×107/L DU145细胞24,48,72 h后,采用四甲基偶氮唑盐法(MTT)检测广藿香醇对细胞的生长抑制作用;透射电镜观察药物诱导细胞凋亡形态变化;Annexin V-FITC,PI双标记法流式细胞仪检测药物诱发细胞凋亡的改变;Western blot检测半胱氨酸天冬氨酸蛋白酶3(Caspase-3)、B细胞淋巴瘤/白血病-2蛋白(Bcl-2)、Bcl-2关联X蛋白(Bax)、凋亡抑制蛋白Livin的表达。结果:MTT法检测提示广藿香醇处理组细胞增殖抑制作用明显,10,20,40,80,160 mg·L-1广藿香醇对DU145的24,48,72 h抑制率分别为5.73%,16.67%,22.61%;13.42%,25.03%,39.68%;25.92%,31.46%,52.76%;39.61%,54.68%,73.52%;56.42%,77.35%,91.58%,呈剂量-时间依赖性(P<0.05)。透射电镜显示药物作用后细胞出现凋亡形态改变。流式细胞仪检测提示广藿香醇作用使细胞凋亡率明显升高,与对照组比较有统计学意义(P<0.05)。Western blot检测提示广藿香醇可增强细胞Caspase-3,Bax的表达,下调Livin,Bcl-2蛋白的表达。结论:广藿香醇能抑制DU145细胞增殖,其作用机制可能与诱导细胞凋亡效应有关。
引用
收藏
页码:165 / 169
页数:5
相关论文
共 7 条
[1]
Patchouli alcohol; an essential oil of Pogostemon cablin ; exhibits anti-tumorigenic activity in human colorectal cancer cells[J] Jin Boo Jeong;Jieun Choi;Zhiyuan Lou;Xiaojing Jiang;Seong-Ho Lee International Immunopharmacology 2013,
[2]
Anti-inflammatory activity of patchouli alcohol in RAW264.7 and HT-29 cells[J] Jin Boo Jeong;Yong Kyu Shin;Seong-Ho Lee Food and Chemical Toxicology 2013,
[3]
Antifungal Effect of Allium tuberosum ; Cinnamomum cassia; and Pogostemon cablin Essential Oils and Their Components Against Population of Aspergillus Species[J] Dragana Kocevski;Muying Du;Jianquan Kan;Chengjun Jing;Ines La?anin;Hrvoje Pavlovi? Journal of Food Science 2013,
[4]
Antidepressant effect of Valeriana wallichii patchouli alcohol chemotype in mice: Behavioural and biochemical evidence[J] Sangeeta Pilkhwal Sah;Chandra S. Mathela;Kanwaljit Chopra Journal of Ethnopharmacology 2011,
[5]
Safety and efficacy of docetaxel; estramustine phosphate and hydrocortisone in hormone‐refractory prostate cancer patients[J] YoshihiroNakagami;MakotoOhori;NoboruSakamoto;ShojiKoga;RiuHamada;TadashiHatano;MasaakiTachibana International Journal of Urology 2010,
[6]
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer[J] Masanori Noguchi;Tatsuyuki Kakuma;Hirotsugu Uemura;Yasutomo Nasu;Hiromi Kumon;Yasuhiko Hirao;Fukuko Moriya;Shigetaka Suekane;Kei Matsuoka;Nobukazu Komatsu;Shigeki Shichijo;Akira Yamada;Kyogo Itoh Cancer Immunology; Immunotherapy 2010,
[7]
Epidemiology of prostate cancer[J] E.David Crawford Urology 2003,